BioCentury | Oct 6, 2018
Finance

Seeking validation

...Removing burn eschar for hospitalized patients with severe burns Top-line Ph III DETECT data YE18 Meiji Seika Pharma...
BioCentury | Jul 20, 2018
Financial News

Spero raises $75M follow-on

...is an oral reformulation of Orapenem tebipenem pivoxil, a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
BioCentury | Jul 16, 2018
Company News

Spero nabs funding for antibiotic

...is an oral reformulation of Orapenem tebipenem pivoxil, a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
BioCentury | Jul 13, 2018
Financial News

Follow-on roundup: Myovant, CytomX, Spero

...is an oral reformulation of Orapenem tebipenem pivoxil, a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
BioCentury | May 18, 2018
Company News

Meiji launches Episil in Japan

...Tokyo:4597), Tokyo, Japan Meiji Seika Pharma Co. Ltd., Tokyo, Japan Business: Neurology Shannon Lehnbeuter episil (SP-03, episil oral spray) Camurus AB Meiji Seika Pharma...
BioCentury | Feb 9, 2018
Clinical News

Eisai, Meiji Seika's safinamide meets in Phase II/III for PD

...Eisai Co. Ltd. (Tokyo:4523) and Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) reported preliminary data from a Phase...
...reducing glutamatergic activity. Newron Pharmaceuticals S.p.A. (SIX:NWRN), Bresso, Italy Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Meiji Seika Pharma...
...responder rate and safety Status: Preliminary Phase II/III data Milestone: Submit MAA (2018) Chris Lieu safinamide Xadago Eisai Co. Ltd. Meiji Seika Pharma...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 10, 2017
Financial News

Spero raises $77M in IPO

...is an oral reformulation of Orapenem tebipenem pivoxil, a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
BioCentury | Nov 2, 2017
Financial News

Spero sags after $77M listing

...is an oral reformulation of Orapenem tebipenem pivoxil, a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
BioCentury | Oct 13, 2017
Financial News

Spero aiming for $86.3M IPO

...an oral reformulation of Orapenem tebipenem pivoxil , a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
...SR One, Atlas Venture , GV and Lundbeckfond. Spero Therapeutics LLC , Cambridge, Mass Mary Romeo SPR741 Atlas Venture Meiji Seika Pharma...
Items per page:
1 - 10 of 65
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Removing burn eschar for hospitalized patients with severe burns Top-line Ph III DETECT data YE18 Meiji Seika Pharma...
BioCentury | Jul 20, 2018
Financial News

Spero raises $75M follow-on

...is an oral reformulation of Orapenem tebipenem pivoxil, a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
BioCentury | Jul 16, 2018
Company News

Spero nabs funding for antibiotic

...is an oral reformulation of Orapenem tebipenem pivoxil, a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
BioCentury | Jul 13, 2018
Financial News

Follow-on roundup: Myovant, CytomX, Spero

...is an oral reformulation of Orapenem tebipenem pivoxil, a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
BioCentury | May 18, 2018
Company News

Meiji launches Episil in Japan

...Tokyo:4597), Tokyo, Japan Meiji Seika Pharma Co. Ltd., Tokyo, Japan Business: Neurology Shannon Lehnbeuter episil (SP-03, episil oral spray) Camurus AB Meiji Seika Pharma...
BioCentury | Feb 9, 2018
Clinical News

Eisai, Meiji Seika's safinamide meets in Phase II/III for PD

...Eisai Co. Ltd. (Tokyo:4523) and Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) reported preliminary data from a Phase...
...reducing glutamatergic activity. Newron Pharmaceuticals S.p.A. (SIX:NWRN), Bresso, Italy Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Meiji Seika Pharma...
...responder rate and safety Status: Preliminary Phase II/III data Milestone: Submit MAA (2018) Chris Lieu safinamide Xadago Eisai Co. Ltd. Meiji Seika Pharma...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 10, 2017
Financial News

Spero raises $77M in IPO

...is an oral reformulation of Orapenem tebipenem pivoxil, a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
BioCentury | Nov 2, 2017
Financial News

Spero sags after $77M listing

...is an oral reformulation of Orapenem tebipenem pivoxil, a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
BioCentury | Oct 13, 2017
Financial News

Spero aiming for $86.3M IPO

...an oral reformulation of Orapenem tebipenem pivoxil , a carbapenem-class antibiotic marketed in Japan by Meiji Seika Pharma...
...SR One, Atlas Venture , GV and Lundbeckfond. Spero Therapeutics LLC , Cambridge, Mass Mary Romeo SPR741 Atlas Venture Meiji Seika Pharma...
Items per page:
1 - 10 of 65